Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05948826 Recruiting - Colorectal Cancer Clinical Trials

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Start date: September 29, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer

NCT ID: NCT05935098 Recruiting - Solid Tumor Clinical Trials

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

Start date: August 21, 2023
Phase: Phase 1
Study type: Interventional

This study aims to test the safety, tolerability, and preliminary anti-tumor activity of BGB-A3055, either alone or in combination with Tislelizumab in participants with advanced or metastatic solid tumors.

NCT ID: NCT05933265 Recruiting - Clinical trials for Advanced Solid Tumor

Study of LP-184 in Patients With Advanced Solid Tumors

Start date: June 9, 2023
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184.

NCT ID: NCT05932862 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors

Start date: August 17, 2023
Phase: Phase 1
Study type: Interventional

This is a FIH, multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as PK and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in subjects with advanced solid tumors.

NCT ID: NCT05916248 Recruiting - Clinical trials for Advanced Solid Tumor

Personalized Tumor Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

Start date: May 18, 2023
Phase: Phase 1
Study type: Interventional

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of advanced solid tumors. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

NCT ID: NCT05911464 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Start date: March 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.

NCT ID: NCT05909241 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of BA1202 in Patients With Advanced Solid Tumors

Start date: August 16, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, single-arm phase I study in patients with advanced solid tumors which consists of a dose escalation part (Part A) and a dose extension part (Part B). Part A aims to evaluate the safety and tolerability of BA1202, and determine the MTD. Part B will also evaluate the preliminary efficacy of BA1202.

NCT ID: NCT05906862 Recruiting - Clinical trials for Advanced Solid Tumor

AMT-253 in Patients With Selected Advanced Solid Tumours

Start date: November 6, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors

NCT ID: NCT05902988 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Start date: October 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

NCT ID: NCT05901285 Recruiting - Clinical trials for Advanced Solid Tumor

Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors

Start date: November 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) in patients with advanced solid tumors. VAX014 is a targeted oncolytic agent designed to kill tumor cells following intratumoral injection into advanced solid tumors.